With $608M divestment, Hutchmed continues to focus on ADC development
2nd January 2025 Uncategorised 0In a move designed to advance its pipeline and its “innovative medicines business,” Chinese biotech Hutchmed will divest its 45% interest in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for $608 million. SHPL is a commercially focused joint venture that primarily sells
read more